{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:03:35Z","timestamp":1777277015261,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-026-07771-z","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:21:05Z","timestamp":1771287665000},"page":"3999-4014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Meningioma theranostics: a retrospective analysis of somatostatin receptor PET\/CT imaging and peptide receptor radionuclide therapy"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6984-0687","authenticated-orcid":false,"given":"L.","family":"Degryse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8941-4619","authenticated-orcid":false,"given":"L.","family":"Teles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9576-9917","authenticated-orcid":false,"given":"S.","family":"De Vleeschouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5906-1113","authenticated-orcid":false,"given":"L.","family":"Boeckxstaens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3602-9078","authenticated-orcid":false,"given":"S.","family":"Jentjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0907-7384","authenticated-orcid":false,"given":"W.","family":"Deckers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8746-2691","authenticated-orcid":false,"given":"M.","family":"Lambrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8584-4189","authenticated-orcid":false,"given":"J. F.","family":"Daisne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5200-7245","authenticated-orcid":false,"given":"K.","family":"Van Laere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8824-8697","authenticated-orcid":false,"given":"A. J. A. T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Clement","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7453-0229","authenticated-orcid":false,"given":"K.","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6080-1577","authenticated-orcid":false,"given":"C. M.","family":"Deroose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"7771_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ncl.2018.04.001","volume":"36","author":"JS Barnholtz-Sloan","year":"2018","unstructured":"Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of brain tumors. Neurol Clin. 2018;36:395\u2013419. https:\/\/doi.org\/10.1016\/j.ncl.2018.04.001.","journal-title":"Neurol Clin"},{"key":"7771_CR2","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/cncr.35279","volume":"130","author":"AL Hsieh","year":"2024","unstructured":"Hsieh AL, Bi WL, Ramesh V, Brastianos PK, Plotkin SR. Evolving concepts in meningioma management in the era of genomics. Cancer. 2024;130:2586\u2013600. https:\/\/doi.org\/10.1002\/cncr.35279.","journal-title":"Cancer"},{"key":"7771_CR3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro Oncol"},{"key":"7771_CR4","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23:1821\u201334. https:\/\/doi.org\/10.1093\/neuonc\/noab150.","journal-title":"Neuro Oncol"},{"key":"7771_CR5","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1007\/s00259-023-06315-z","volume":"50","author":"M Unterrainer","year":"2023","unstructured":"Unterrainer M, Kunte SC, Unterrainer LM, Holzgreve A, Delker A, Lindner S, et al. Next-generation PET\/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE. Eur J Nucl Med Mol Imaging. 2023;50:3390\u20139. https:\/\/doi.org\/10.1007\/s00259-023-06315-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7771_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2967\/jnumed.123.265622","volume":"64","author":"H Leupe","year":"2023","unstructured":"Leupe H, Ahenkorah S, Dekervel J, Unterrainer M, Van Cutsem E, Verslype C, et al. (18)F-labeled somatostatin analogs as PET tracers for the somatostatin receptor: ready for clinical use. J Nucl Med. 2023;64:835\u201341. https:\/\/doi.org\/10.2967\/jnumed.123.265622.","journal-title":"J Nucl Med"},{"key":"7771_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00259-023-06391-1","volume":"51","author":"P Wang","year":"2023","unstructured":"Wang P, Liu S, Li X, Liu X, Li S, Wu Z, et al. The usefulness of [(68) Ga]Ga-DOTA-JR11 PET\/CT in patients with meningioma: comparison with MRI. Eur J Nucl Med Mol Imaging. 2023;51:218\u201325. https:\/\/doi.org\/10.1007\/s00259-023-06391-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7771_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2967\/jnumed.123.266817","volume":"65","author":"C Eigler","year":"2024","unstructured":"Eigler C, McDougall L, Bauman A, Bernhardt P, Hentschel M, Blackham KA, et al. Radiolabeled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with therapy-resistant meningioma: PROMENADE phase 0 study. J Nucl Med. 2024;65:573\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.266817.","journal-title":"J Nucl Med"},{"key":"7771_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2967\/jnumed.114.149120","volume":"56","author":"W Rachinger","year":"2015","unstructured":"Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, P\u00f6schl J, et al. Increased 68Ga-DOTATATE uptake in pet imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56:347\u201353. https:\/\/doi.org\/10.2967\/jnumed.114.149120.","journal-title":"J Nucl Med"},{"key":"7771_CR10","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1007\/s00259-024-06783-x","volume":"51","author":"NL Albert","year":"2024","unstructured":"Albert NL, Preusser M, Traub-Weidinger T, Tolboom N, Law I, Palmer JD, et al. Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0. Eur J Nucl Med Mol Imaging. 2024;51:3662\u201379. https:\/\/doi.org\/10.1007\/s00259-024-06783-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7771_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijrobp.2024.12.003","volume":"122","author":"HK Perlow","year":"2025","unstructured":"Perlow HK, Raleigh DR, Wang TJC, Pollom EL, Milano MT, Breen WG, et al. Consensus radiation treatment planning guidelines using (68)Ga-DOTATATE PET\/CT for resected meningiomas. Int J Radiat Oncol Biol Phys. 2025;122:150\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.12.003.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7771_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ijrobp.2022.04.009","volume":"113","author":"HK Perlow","year":"2022","unstructured":"Perlow HK, Siedow M, Gokun Y, McElroy J, Matsui J, Zoller W, et al. (68)Ga-DOTATATE PET-based radiation contouring creates more precise radiation volumes for patients with meningioma. Int J Radiat Oncol Biol Phys. 2022;113:859\u201365. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.04.009.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7771_CR13","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.2967\/jnumed.116.179234","volume":"57","author":"CM Deroose","year":"2016","unstructured":"Deroose CM, Hindi\u00e9 E, Kebebew E, Goichot B, Pacak K, Ta\u00efeb D, et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med. 2016;57:1949\u201356. https:\/\/doi.org\/10.2967\/jnumed.116.179234.","journal-title":"J Nucl Med"},{"key":"7771_CR14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.269633","author":"NL Albert","year":"2025","unstructured":"Albert NL, Tabouret E, Le Rhun E, Sahm F, Furtner J, Tonn JC, et al. [ 177 Lu]Lu-DOTATATE for recurrent meningioma (LUMEN-1, EORTC-2334-BTG): study protocol for a randomized phase II trial. J Nucl Med. 2025. https:\/\/doi.org\/10.2967\/jnumed.125.269633.","journal-title":"J Nucl Med"},{"key":"7771_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.122.264563","volume":"64","author":"E Pauwels","year":"2023","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, et al. (18)F-AlF-NOTA-octreotide outperforms (68)Ga-DOTATATE\/NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study. J Nucl Med. 2023;64:632\u20138. https:\/\/doi.org\/10.2967\/jnumed.122.264563.","journal-title":"J Nucl Med"},{"key":"7771_CR16","doi-asserted-by":"publisher","first-page":"7089","DOI":"10.1007\/s00330-023-09697-8","volume":"33","author":"C Boursier","year":"2023","unstructured":"Boursier C, Zaragori T, Bros M, Bordonne M, Melki S, Taillandier L, et al. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy. Eur Radiol. 2023;33:7089\u201398. https:\/\/doi.org\/10.1007\/s00330-023-09697-8.","journal-title":"Eur Radiol"},{"key":"7771_CR17","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2967\/jnumed.123.266956","volume":"65","author":"S Severi","year":"2024","unstructured":"Severi S, Grassi I, Bongiovanni A, Nicolini S, Marini I, Arpa D, et al. Peptide receptor radionuclide therapy in advanced refractory meningiomas: efficacy and toxicity in a long follow-up. J Nucl Med. 2024;65:1409\u201315. https:\/\/doi.org\/10.2967\/jnumed.123.266956.","journal-title":"J Nucl Med"},{"key":"7771_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2967\/jnumed.117.189712","volume":"59","author":"H Bergsma","year":"2018","unstructured":"Bergsma H, van Lom K, Raaijmakers M, Konijnenberg M, Kam B, Teunissen JJM, et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with (177)Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2018;59:452\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.189712.","journal-title":"J Nucl Med"},{"key":"7771_CR19","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1007\/s00701-021-04919-8","volume":"163","author":"S Nakasu","year":"2021","unstructured":"Nakasu S, Notsu A, Nakasu Y. Prevalence of incidental meningiomas and gliomas on MRI: a meta-analysis and meta-regression analysis. Acta Neurochir (Wien). 2021;163:3401\u201315. https:\/\/doi.org\/10.1007\/s00701-021-04919-8.","journal-title":"Acta Neurochir (Wien)"},{"key":"7771_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15101204","author":"CM Iacovitti","year":"2025","unstructured":"Iacovitti CM, Muoio B, Albano D, Rizzo A, Cuzzocrea M, Paone G, et al. The prevalence and significance of incidental positron emission tomography findings in the brain using radiotracers other than [(18)F]FDG: a systematic review and meta-analysis. Diagnostics. 2025. https:\/\/doi.org\/10.3390\/diagnostics15101204.","journal-title":"Diagnostics"},{"key":"7771_CR21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270115","author":"R Ebner","year":"2025","unstructured":"Ebner R, Braach J, R\u00fcbenthaler J, Cyran CC, Sheikh GT, Brendel M, et al. Retrospective evaluation of the correlation between somatostatin receptor PET\/CT and histopathology in patients with suspected intracranial meningiomas. J Nucl Med. 2025. https:\/\/doi.org\/10.2967\/jnumed.125.270115.","journal-title":"J Nucl Med"},{"key":"7771_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clinimag.2020.04.026","volume":"66","author":"M Roytman","year":"2020","unstructured":"Roytman M, Pisapia DJ, Liechty B, Lin E, Skafida M, Magge RS, et al. Somatostatin receptor-2 negative meningioma: pathologic correlation and imaging implications. Clin Imaging. 2020;66:18\u201322. https:\/\/doi.org\/10.1016\/j.clinimag.2020.04.026.","journal-title":"Clin Imaging"},{"key":"7771_CR23","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.2967\/jnumed.124.267767","volume":"65","author":"H Li","year":"2024","unstructured":"Li H, Badawi RD, Cherry SR, Fontaine K, He L, Henry S, et al. Performance characteristics of the NeuroEXPLORER, a next-generation human brain PET\/CT imager. J Nucl Med. 2024;65:1320\u20136. https:\/\/doi.org\/10.2967\/jnumed.124.267767.","journal-title":"J Nucl Med"},{"key":"7771_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/01676830.2014.959185","volume":"34","author":"A Klingenstein","year":"2015","unstructured":"Klingenstein A, Haug AR, Miller C, Hintschich C. Ga-68-DOTA-TATE PET\/CT for discrimination of tumors of the optic pathway. Orbit. 2015;34:16\u201322. https:\/\/doi.org\/10.3109\/01676830.2014.959185.","journal-title":"Orbit"},{"key":"7771_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133305","author":"J Graef","year":"2021","unstructured":"Graef J, Furth C, Kluge AK, Acker G, Kord M, Zimmermann Z, et al. 68Ga-DOTATOC-PET\/MRI\u2014a secure one-stop shop imaging tool for robotic radiosurgery treatment planning in patients with optic nerve sheath meningioma. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13133305.","journal-title":"Cancers (Basel)"},{"key":"7771_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07476-9","author":"N Mansour","year":"2025","unstructured":"Mansour N, Joram J, Grawe F, Hinterberger A, R\u00fcbenthaler J, Klambauer K, et al. Validation of SUV thresholds in [1\u2078F]SiTATE PET\/CT for accurate meningioma segmentation. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07476-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7771_CR27","first-page":"13185","volume":"8","author":"CB Silva","year":"2015","unstructured":"Silva CB, Ongaratti BR, Trott G, Haag T, Ferreira NP, Le\u00e3es CG, et al. Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. Int J Clin Exp Pathol. 2015;8:13185\u201392.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"7771_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-023-01003-3","volume":"13","author":"L Boeckxstaens","year":"2023","unstructured":"Boeckxstaens L, Pauwels E, Vandecaveye V, Deckers W, Cleeren F, Dekervel J, et al. Prospective comparison of [18F]AlF-NOTA-octreotide PET\/MRI to [68Ga]Ga-DOTATATE PET\/CT in neuroendocrine tumor patients. EJNMMI Res. 2023;13(1):53. https:\/\/doi.org\/10.1186\/s13550-023-01003-3.","journal-title":"EJNMMI Res"},{"key":"7771_CR29","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-020-04918-4","volume":"47","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, et al. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020;47:3033\u201346. https:\/\/doi.org\/10.1007\/s00259-020-04918-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7771_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2967\/jnumed.120.249607","volume":"62","author":"C Mirian","year":"2021","unstructured":"Mirian C, Duun-Henriksen AK, Maier A, Pedersen MM, Jensen LR, Bashir A, et al. Somatostatin receptor\u2013targeted radiopeptide therapy in treatment-refractory meningioma: individual patient data meta-analysis. J Nucl Med. 2021;62:507\u201313. https:\/\/doi.org\/10.2967\/jnumed.120.249607.","journal-title":"J Nucl Med"},{"key":"7771_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07555-x","author":"C Boursier","year":"2025","unstructured":"Boursier C, Zaragori T, Garabedian N, Blonski M, Obara T, Taillandier L, et al. [(177)Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07555-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7771_CR32","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/neuonc\/noab243","volume":"24","author":"M Preusser","year":"2022","unstructured":"Preusser M, Silvani A, Le Rhun E, Soffietti R, Lombardi G, Sepulveda JM, et al. Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro Oncol. 2022;24:755\u201367. https:\/\/doi.org\/10.1093\/neuonc\/noab243.","journal-title":"Neuro Oncol"},{"key":"7771_CR33","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/neuonc\/now060","volume":"18","author":"K Seystahl","year":"2016","unstructured":"Seystahl K, Stoecklein V, Sch\u00fcller U, Rushing E, Nicolas G, Sch\u00e4fer N, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake. Neuro Oncol. 2016;18:1538\u201347. https:\/\/doi.org\/10.1093\/neuonc\/now060.","journal-title":"Neuro Oncol"},{"key":"7771_CR34","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2967\/jnumed.121.262491","volume":"63","author":"EPA Vonken","year":"2022","unstructured":"Vonken EPA, Bruijnen RCG, Snijders TJ, Seute T, Lam M, Keizer B, et al. Intraarterial administration boosts (177)Lu-HA-DOTATATE accumulation in salvage meningioma patients. J Nucl Med. 2022;63:406\u20139. https:\/\/doi.org\/10.2967\/jnumed.121.262491.","journal-title":"J Nucl Med"},{"key":"7771_CR35","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.2967\/jnumed.124.268217","volume":"65","author":"A Amerein","year":"2024","unstructured":"Amerein A, Maurer C, Kircher M, G\u00e4ble A, Krebold A, Rinscheid A, et al. Intraarterial administration of peptide receptor radionuclide therapy in patients with advanced meningioma: initial safety and efficacy. J Nucl Med. 2024;65:1911\u20136. https:\/\/doi.org\/10.2967\/jnumed.124.268217.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07771-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07771-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07771-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:26:03Z","timestamp":1777274763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07771-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7771"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07771-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study protocol was reviewed and approved by the institutional ethics committee of University Hospitals Leuven (protocol number S68916). The requirement to obtain informed consent for participation and publication was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"C.M. Deroose is an employee of UZ Leuven. He is\/has been a consultant for (fees received by institution): Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, IRE, Terumo, PSI CRO, Immedica Pharma, Molecular Partners, Nuclear Research and consultancy, Telix and ITM. His institution has received travel fees from: GE Healthcare, Sirtex.\u00a0P.M. Clement reports fees (to institution) from Bayer, Merck, MSD, Leo Pharma, Rakuten Medical, Takeda, Servier, and Bristol Myers Squibb (BMS); grants from AstraZeneca outside the submitted work; and fees for occasional advice to government agencies such as FAGG\/EMA, and as a member of CTG\/CRM in Belgium. A.J.A.T Braat is Consultant for Boston Scientific, Terumo, GE Healthcare, Telix Pharmaceuticals. Research support from Boston Scientific, Ariceum Therapeutics, Telix Pharmaceuticals and Siemens Healthineers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}